Lv1
60 积分 2021-10-18 加入
Efficacy and Safety of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in Daratumumab-Naïve Relapsed Multiple Myeloma: Multicenter Real-World Experience
2个月前
已关闭
A first-in-class JAK/ROCK inhibitor, Rovadicitinib in patients with myelofibrosis who were refractory or relapsed or intolerant to Ruxolitinib: A single-arm, multicenter, open-label, phase Ib study
5个月前
已完结
Ph-Positive Acute Lymphoblastic Leukemia — 25 Years of Progress
5个月前
已完结
Coagulation Factor VII Deficiency: A Review of the Clinical Implications and Approaches to Replacement Therapy and Prophylaxis
11个月前
已完结
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma
11个月前
已完结
Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial
11个月前
已完结
皖公网安备34019202002308
